

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1829R1

Serial No.

09/863,101

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Mass, Robert D.

Filing Date

18 May 2001

Group

1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	320	2002/0064785	30.05.02	Mass, R.			
	321	2002/0090662	11.07.02	Ralph, P.			
	322	2002/0141993	03.10.02	Ashkenazi et al.			
	323	2002/0142328	03.10.02	Danenberg, K.			
	324	2002/0192211	19.12.02	Hudziak et al.			
	325	2003/0059790	27.03.03	Jaffee et al.			
	326	2003/0108545	12.06.03	Rockwell et al.			
	327	2003/0134344	17.07.03	Mass, R.			
	328	2003/0144252	31.07.03	Furr, B.			
	329	2003/0152987	14.08.03	Cohen et al.			
	330	2003/0157097	21.08.03	Noguchi et al.			
	331	2003/0170234A1	11.09.03	Hellmann			
	332	2003/0211530	13.11.03	Danenberg, K.			
	333	2004/0037823	26.02.04	Paton et al.			
	334	6,387,371 B1	14.05.02	Hudziak et al.			
	335	6,399,063 B1	04.06.02	Hudziak et al.			
	336	6,407,213	18.06.02	Carter et al.			
	337	6,573,043	03.06.03	Cohen et al.			
	338	6,602,670	05.08.03	Danenberg, K.			
	339	6,627,196	30.09.03	Baughman et al.			
	340	6,632,979	14.10.03	Erickson et al.			
	341	6,719,971	13.04.04	Carter et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	342	WO 01/76630	18.10.01	PCT (ENGLISH ABSTRACT ON COVER)				
	343	WO 01/89566	29.11.01	PCT				
	344	WO 02/055106	18.07.02	PCT				
	345	WO 02/45653	13.06.02	PCT				
	346	WO 99/48527	30.09.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	347	Cobleigh et al., "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease" <u>Journal of Clinical Oncology</u> 17(9):2639-2648 (Sep 1999)					
	348	Slamon et al., "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2" <u>New England J. of Medicine</u> 344(11):783-792 (Mar 15, 2001)					
	349	Statement Regarding HERCEPTIN Clinical Trials pps. 1 (2004)					

Examiner

Date Considered

9/14/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	Mail Date Cancelled NOV 08 2004	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1829R1	Serial No. 09/863,101
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Mass, Robert D.	
			Filing Date 18 May 2001	Group 1642

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
319	6,582,919	24.06.03	Danenberg, K.			
COPY						

Examiner <i>[Signature]</i>	Date Considered 9/14/05
--------------------------------	----------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1829R1

Serial No.

09/863,101

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Mass, Robert D.

Filing Date

18 May 2001

Group

1642

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

350 Agus et al., "Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth"
Cancer Cell 2(2):127-137 (Aug 2002)

Examiner

Date Considered

9/14/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.